JP2005513416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513416A5 JP2005513416A5 JP2003525032A JP2003525032A JP2005513416A5 JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5 JP 2003525032 A JP2003525032 A JP 2003525032A JP 2003525032 A JP2003525032 A JP 2003525032A JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- amino acid
- acid sequence
- proline
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR7431 | 2001-09-03 | ||
| AUPR7431A AUPR743101A0 (en) | 2001-09-03 | 2001-09-03 | A cancer therapeutic |
| AUPR7430 | 2001-09-03 | ||
| AUPR7430A AUPR743001A0 (en) | 2001-09-03 | 2001-09-03 | Diagnosis and treatment of irritable bowel syndrome |
| AUPCT/AU02/00061 | 2002-01-17 | ||
| PCT/AU2002/000061 WO2002057306A1 (en) | 2001-01-17 | 2002-01-17 | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| PCT/AU2002/001204 WO2003020762A1 (en) | 2001-09-03 | 2002-09-03 | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513416A JP2005513416A (ja) | 2005-05-12 |
| JP2005513416A5 true JP2005513416A5 (https=) | 2008-05-15 |
| JP4467973B2 JP4467973B2 (ja) | 2010-05-26 |
Family
ID=41706691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003525032A Expired - Lifetime JP4467973B2 (ja) | 2001-09-03 | 2002-09-03 | 非機能性ｐ２ｘ７リセプターに対応する抗体、癌及びその他の症状の診断及び治療 |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JP4467973B2 (https=) |
| CN (2) | CN100497386C (https=) |
| AU (1) | AU2002322192B2 (https=) |
| CA (1) | CA2459348C (https=) |
| MY (1) | MY142283A (https=) |
| NZ (2) | NZ565994A (https=) |
| TW (1) | TWI329648B (https=) |
| WO (1) | WO2003020762A1 (https=) |
| ZA (1) | ZA200402630B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1360203B1 (en) | 2001-01-17 | 2008-12-24 | Intreat Pty Limited | Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions |
| WO2004053426A1 (en) * | 2002-12-05 | 2004-06-24 | Kla-Tencor Technologies Corporation | Apparatus and methods for detecting overlay errors using scatterometry |
| WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| US8124730B1 (en) | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
| US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2008043146A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
| JP2010505426A (ja) * | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ |
| AU2008299594B2 (en) * | 2007-09-14 | 2013-10-03 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| AU2013238152B2 (en) * | 2007-09-14 | 2015-09-24 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| AU2008299593B2 (en) | 2007-09-14 | 2013-04-18 | Biosceptre International Limited | Novel P2X7 epitopes |
| BRPI0915367B8 (pt) | 2008-07-04 | 2021-05-25 | Biosceptre International Ltd | peptídeo anti-p2x7 |
| CN101469352B (zh) * | 2008-08-29 | 2011-12-21 | 苏州福英基因科技有限公司 | 一种早期子宫癌原位杂交检测试剂盒 |
| ES2904911T3 (es) * | 2009-08-20 | 2022-04-06 | Biosceptre Aust Pty Ltd | Anticuerpos anti-receptor P2X7 y fragmentos de los mismos |
| JP5992831B2 (ja) * | 2009-12-24 | 2016-09-14 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 |
| CN106310245A (zh) * | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
| US9566318B2 (en) * | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| EP3347474B1 (en) | 2015-09-11 | 2020-11-04 | Biosceptre (UK) Limited | Chimeric antigen receptors and uses thereof |
| CN109862883A (zh) * | 2016-10-21 | 2019-06-07 | 生物权威（英国）有限公司 | 细胞毒性颗粒 |
| EP3797164A4 (en) | 2018-05-21 | 2022-03-02 | Biosceptre (Aust) Pty Ltd | CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| JP2024513485A (ja) * | 2021-04-08 | 2024-03-25 | バイオセプター （オースト） プロプライエタリー・リミテッド | 免疫細胞活性を制御する方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| EP1360203B1 (en) * | 2001-01-17 | 2008-12-24 | Intreat Pty Limited | Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions |
-
2002
- 2002-09-03 NZ NZ565994A patent/NZ565994A/en not_active IP Right Cessation
- 2002-09-03 CN CNB028214331A patent/CN100497386C/zh not_active Expired - Lifetime
- 2002-09-03 JP JP2003525032A patent/JP4467973B2/ja not_active Expired - Lifetime
- 2002-09-03 CN CN2008102142942A patent/CN101445555B/zh not_active Expired - Lifetime
- 2002-09-03 NZ NZ549019A patent/NZ549019A/en not_active IP Right Cessation
- 2002-09-03 CA CA2459348A patent/CA2459348C/en not_active Expired - Lifetime
- 2002-09-03 TW TW091120122A patent/TWI329648B/zh not_active IP Right Cessation
- 2002-09-03 AU AU2002322192A patent/AU2002322192B2/en not_active Expired
- 2002-09-03 WO PCT/AU2002/001204 patent/WO2003020762A1/en not_active Ceased
- 2002-09-04 MY MYPI20023310A patent/MY142283A/en unknown
-
2004
- 2004-04-02 ZA ZA2004/02630A patent/ZA200402630B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005513416A5 (https=) | ||
| Korb et al. | Use of monoclonal antibody–IRDye800CW bioconjugates in the resection of breast cancer | |
| CN100497385C (zh) | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 | |
| EP3634500B1 (en) | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof | |
| CN100497386C (zh) | 非功能性p2x7受体的抗体及其应用 | |
| Hartimath et al. | Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft | |
| Chen et al. | Detection of Barrett’s neoplasia with a near-infrared fluorescent heterodimeric peptide | |
| JP2024520616A (ja) | 交流電場とトラスツズマブの組合せを用いて処置するための組成物及び方法 | |
| CN112661812B (zh) | 一种kk-lc-1抗原靶向结合肽及其衍生物、探针与应用 | |
| Sputa‐Grzegrzolka et al. | Laugier‐Hunziker syndrome: a case report of the pediatric patient and review of the literature | |
| Gan et al. | A Phase 1 and Biodistribution Study of ABT-806i, An 111Indium-Labeled Conjugate of theTumor-Specific Anti-EGFR Antibody ABT-806 | |
| Pasanen et al. | Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study | |
| Koo et al. | Ornithine decarboxylase levels in the rectal mucosa of patients with colonic neoplasia | |
| Kilpi et al. | The expression of c‐erbB‐2 protein in the keratinocytes of oral mucosal lichen planus | |
| US20240293573A1 (en) | Pharmaceutical composition for treating cancer, containing lipid-photothermal nanoparticle having antibody bound to surface | |
| WO2020237491A1 (en) | Composition and methods to treat ectodermal dysplasia 2, clouston type | |
| CN121422259A (zh) | 一种基于抗组织因子抗体的诊断放射性药物及其制备方法和应用 | |
| Wang et al. | General Introduction of PET/CT of Neck Neoplasms | |
| WO2024155810A1 (en) | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy | |
| Henry | Production, characterisation and clinical application of monoclonal antibodies to the human oestrogen and progesterone receptors. | |
| Glass | Mottled Skin Changes | |
| Swanston et al. | Clinical PET/CT in oncology | |
| Riedel et al. | Expression of epidermal growth factor receptor in lymph node metastases of head and neck squamous cell carcinomas | |
| Kumar et al. | Primary oral malignant melanoma-a case report | |
| Tuttle et al. | Thyroid cancer recurrence rates are similar when thyroid remnant ablation is performed after thyroid hormone withdrawal or recombinant human TSH stimulation |